# Treatment of Nosocomial COVID-19

> **NCT04748588** · PHASE4 · TERMINATED · sponsor: **University of Calgary** · enrollment: 46 (actual)

## Conditions studied

- Covid19
- Nosocomial Infection
- SARS-CoV2 Infection

## Interventions

- **DRUG:** Anti-SARS-CoV-2 mAb

## Key facts

- **NCT ID:** NCT04748588
- **Lead sponsor:** University of Calgary
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-02-12
- **Primary completion:** 2022-01-31
- **Final completion:** 2022-01-31
- **Target enrollment:** 46 (ACTUAL)
- **Why stopped:** Equipoise requirement no longer met.
- **Last updated:** 2023-04-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04748588

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04748588, "Treatment of Nosocomial COVID-19". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04748588. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*